Achmea Innovation Fund sells portfolio company Organ Assist to XVIVO
The Groningen company Organ Assist, a pioneer in the field of perfusion of donor organs, and the Swedish XVIVO Perfusion are going to join forces. To this end, the listed XVIVO Perfusion will take over 100% of the shares of Organ Assist. The Achmea Innovation Fund thereby waives a 20% interest in Organ Assist. It was originally an investment by De Friesland Participatiefonds, a predecessor of the Achmea Innovation Fund.
Organ Assist develops technology that keeps donated livers and kidneys in better condition and can even increase their quality. The system works so well that considerably more organs offered can be made suitable for transplantation. Ultimately, this means that more patients have the prospect of a new life-saving organ.
XVIVO Perfusion has a leading position in the preservation and perfusion of lungs and hearts. Combining both medtech companies aims to achieve a global leading position with a unique synergy of fluids and pump systems for all major organs (heart, lungs, liver and kidneys).
Positive contribution to a social problem
Katharina Maass, fund manager of the Achmea Innovation Fund about the sale of Organ Assist: “We are pleased that in recent years we have been able to contribute to the positive development of this company and thus to the social problem of the shortage of donor organs. We believe that XVIVO is an excellent player to further expand the activities of Organ Assist and to put organ perfusion on the map worldwide.”
Achmea is the cooperative parent company of Centraal Beheer, Interpolis and Zilveren Kruis, among others. The Achmea Innovation Fund (started on 1 October 2019) focuses on promising, fast-growing startups and scaleups, often based on emerging technologies. The fund provides growth capital to promising (tech) companies that are active in Achmea's strategic domains: health, mobility, housing and financial solutions for now, tomorrow and later. In terms of health, in the future the fund will mainly focus on digital solutions for prevention and strengthening and bringing health closer. In addition to investing, the Achmea Innovation Fund expressly wants to build a long-term partnership with meaningful companies, as is Organ Assist. The fund has an initial size of €100 million.
For more information:
Marco Simmers
Corporate spokesperson Achmea
Telephone 06 - 53 43 87 18